GLP hERG Screening at Metrion Biosciences Background
Metrion Biosciences Cardiac Safety Screening Icon Large 01 01

hiPSC-derived Cardiomyocyte Screening

Successfully detect differences between compounds with low, medium and high proarrhythmic risk profiles

Evaluate the effect of compounds on action potentials recorded from hiPSC-derived cardiomyocytes using conventional manual patch clamp methodology.

Spontaneous or evoked action potentials can be recorded and used to determine the effect of compounds on a range of action potential parameters. The recordings are stable for >30 minutes, which allows the cumulative application of multiple concentrations of each compound.

The manual patch clamp assay generates high fidelity recordings that allow the detection of even subtle changes to the action potential waveform. This helps to successfully discern between compounds with low, medium and high proarrhythmic risk profiles. For example, the figures below show data generated using 50 nM dofetilide, which reveals a significant prolongation of all measured APD values.

iPSC-derived cardiomyocyte action potential screening.
Figure 1. hiPSC-derived cardiomyocyte action potential screening.
Drug effects on iPSC-derived cardiomyocyte responses.
Figure 2. Drug effects on hiPSC-derived cardiomyocyte responses.
Changes in iPSC-derived cardiomyocyte beat stability
Figure 3. Changes in hiPSC-derived cardiomyocyte beat stability.

Ion channel screening resource library

Publications
Videos and Presentations
Posters
Application notes and resources
Wave Background thinner 01 1

Let’s work together

What are your specific GLP hERG Screening requirements?

If you have any questions, or would like to discuss your project, we will put you directly in touch with a member of our scientific team. Contact us today to discover more.